Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Down 7.5 %

GLMD stock opened at $0.35 on Tuesday. The company has a market capitalization of $1.76 million, a price-to-earnings ratio of -0.11 and a beta of 0.87. Galmed Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $7.80. The firm has a 50 day moving average of $0.36 and a two-hundred day moving average of $0.39.

Institutional Trading of Galmed Pharmaceuticals

Large investors have recently modified their holdings of the company. Walleye Capital LLC bought a new stake in shares of Galmed Pharmaceuticals during the 3rd quarter worth $155,000. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Galmed Pharmaceuticals by 158.9% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 63,310 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 38,856 shares during the period. Millennium Management LLC boosted its holdings in shares of Galmed Pharmaceuticals by 218.4% during the 4th quarter. Millennium Management LLC now owns 149,217 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 102,351 shares during the period. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in shares of Galmed Pharmaceuticals during the 1st quarter worth $42,000. 76.14% of the stock is owned by institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.